methamphetamine use disorder (+ hiv): trials, trends and

28
Methamphetamine use disorder (+ HIV): Trials, Trends and Tribulations WHAT-IF? Learning Collaborative September 11, 2019 Paxton Bach MD, MSc, ABIM, FRCPC Clinical Assistant Professor UBC Department of Medicine Vancouver, Canada

Upload: others

Post on 16-Nov-2021

11 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Methamphetamine use disorder (+ HIV): Trials, Trends and

Methamphetamineusedisorder(+HIV):Trials,TrendsandTribulations

WHAT-IF?LearningCollaborativeSeptember11,2019

PaxtonBachMD,MSc,ABIM,FRCPCClinicalAssistantProfessorUBCDepartmentofMedicineVancouver,Canada

Page 2: Methamphetamine use disorder (+ HIV): Trials, Trends and

•  Background•  Physiologyandhealtheffects•  Epidemiology•  Treatment

Outline

Page 3: Methamphetamine use disorder (+ HIV): Trials, Trends and

•  HigherratesofmethuseinpopulationsatriskforHIV–  Upto20%ofMSMmayreportmethusewithinpast6mo1

•  MethuseisassociatedwithanincreasedriskofcontractingHIV–  Higherratesofriskybehaviours(highriskinjectionand/orsexualpractices)2

–  Impaired/alteredimmunity?3

•  MethuseisassociatedwithworseHIVoutcomes–  DecreasedARTadherence,slowerratesofRNAsuppression,decreasedCD4counts,pooroverallhealthoutcomes3,4

1Shoptawetal.Addiction,2007.2Degenhardtetal.IntJDrugPolicy,2009.3Passaroetal.JNeuroimmunePharmacol,2015.4Fairbairnetal.AddictBehav,2011.

Whythefuss?

Page 4: Methamphetamine use disorder (+ HIV): Trials, Trends and

HIVprevalenceamongMSMwhoprimarilyinjectedmethwasalmost50%higherthanamongMSMwhoprimarilyinjectedotherdrugs,andthisassociationwasmediatedbysexualrisk.

Page 5: Methamphetamine use disorder (+ HIV): Trials, Trends and

Background

Page 6: Methamphetamine use disorder (+ HIV): Trials, Trends and

Ephedrasinica

Page 7: Methamphetamine use disorder (+ HIV): Trials, Trends and

Methamphetaminepowder-  POorinsufflated

Methamphetaminebase-POorinjected

Crystalmethamphetamine-Smoked,insufflatedorinjected

Ice,crystal,glass,speed,meth,jib,side,gak,chalk,crank,tina,go,geek,tweak,amp,P2P,zip,shards,goofball*

Half-lifeforall3closeto~10hours!

Methamphetamine

Page 8: Methamphetamine use disorder (+ HIV): Trials, Trends and

Narcolepsy,exhaustion,weight loss,schizophrenia,asthma,morphineaddiction,barbiturate intoxication, alcoholism, excessive anaesthesia administration,migraine, heart block, myasthenia gravis, myotonia, enuresis, dysmenorrhea,Meniere’sdisease,colic,headinjuries,infantilecerebralpalsy,codeineaddiction,tobaccosmoking,pediatricbehaviourissues,Parkinson’sdisease,epilepsy…

Page 9: Methamphetamine use disorder (+ HIV): Trials, Trends and

Physiologyandeffects

Page 10: Methamphetamine use disorder (+ HIV): Trials, Trends and

Pharmacology

Page 11: Methamphetamine use disorder (+ HIV): Trials, Trends and

•  Mania/paranoia/psychosis•  Hypertension,agitation,sweating•  Skin-picking/formication(delusionsofinsectsundertheskin)

•  Abnormalmovement(choreoathetosis,ataxia)

•  Miosis

Acuteintoxication

Page 12: Methamphetamine use disorder (+ HIV): Trials, Trends and

*Societalharms:environmentalhazards/pollution,crime,violence.

Cardiac Infectious Hematologic Gastrointestinal

Chestpain HIV Necrotizingangiitis Acuteliverinjury

CAD Viralhepatitis Mesentericinfarction

Myocardialinfarction MSK Ischemiccolitis

Tachycardia Neurologic “Methmouth” Pancreatitis

Hypertension ICH Rhabdomyolysis

Dysrhythmias Ischemicstroke Traumas Pulmonary

DilatedCMO Seizure Osteomyelitis Pulmonaryedema

Aorticdissection Cognitiveimpairment Pulmonaryhypertension

Infectiveendocarditis Obstetrical

Dermatologic Fetalgrowthrestriction Renal

Genitourinary Picking/excoriations Prematuredelivery Myoglobulinuria

STIs Cellulitis Abruption Necrotizingangiitis

Abscesses

AdaptedfromVearrieretal.DisMon,2012.

Meth-associatedhealthcomplications

Page 13: Methamphetamine use disorder (+ HIV): Trials, Trends and

Volkowetal.AmJPsychiatry,2001.

Neurotoxicity(dopamineneurons)

Page 14: Methamphetamine use disorder (+ HIV): Trials, Trends and

Epidemiology

Page 15: Methamphetamine use disorder (+ HIV): Trials, Trends and

UNODCWorldDrugReport,2019.

Page 16: Methamphetamine use disorder (+ HIV): Trials, Trends and

SAMHSANationalSurveyonDrugUseandHealth,2016.

USNationalSurveyonDruguseandHealth:PrevalenceofIllicitDrugUse

Page 17: Methamphetamine use disorder (+ HIV): Trials, Trends and

DEANationalClandestineLaboratoryRegistry,2004-2012.

MethamphetamineLabDistributionintheUS

Page 18: Methamphetamine use disorder (+ HIV): Trials, Trends and
Page 19: Methamphetamine use disorder (+ HIV): Trials, Trends and

UNODCWorldDrugReport,2019.

Psychostimulant-relatedoverdosedeathsinUS,1999-2017

Page 20: Methamphetamine use disorder (+ HIV): Trials, Trends and

Treatment

Page 21: Methamphetamine use disorder (+ HIV): Trials, Trends and
Page 22: Methamphetamine use disorder (+ HIV): Trials, Trends and

StimulantUseDisorderTreatment

Pharmacologic

Anti-Depressants

Anti-Psychotics

AgonistTherapies

Non-pharmacologic

CBT(+/-MI)

ContingencyManagement

ModafinilMethylphenidate

DextroamphetamineBupropion

AripiprazoleRisperidone

SSRIsMirtazapine

Others:gabapentin,baclofen,vigabatrin,topiramate,ondansetron,naltrexone,ibudilast…

Page 23: Methamphetamine use disorder (+ HIV): Trials, Trends and

StudyDrug EffectPsychostimulants(dexamphetamine,methylphenidate)

9RCTs:maydecreaseuse,craving,and/orseverityofaddiction?

Topiramate 2RCTs:maydecreaseuse,and/orseverity?

Mirtazapine 1RCT:maydecreaseuse?Bupropion 5RCTs:maydecreaseuse?Naltrexone 2RCTs:maydecreaseuseand/or

craving?Modafinil 3RCTs:maydecreaseuse?

AdaptedfromLeeetal.,DrugAlcDep.2018.

*Studieslimitedbyretention,adherence,primaryoutcomes.

Trialmedications

Page 24: Methamphetamine use disorder (+ HIV): Trials, Trends and

TreatmentofStimulantUseDisorder:PsychosocialTreatments

1.  Contingencymanagement2.  Cognitivebehavioural

therapy3.  Motivationalinterviewing4.  Relapseprevention5.  Psychodynamictherapy6.  Combinationsprograms

•  Overallsmalltomoderateeffects(dropoutratesaretypically>40%)

•  Immediateeffectsnoted,long-termbenefitsformethusedisordernotclear

Page 25: Methamphetamine use disorder (+ HIV): Trials, Trends and

TreatmentofStimulantUseDisorder:PsychosocialTreatmentsContingencyManagement

•  Goalistoreducereinforcementprovidedbydrugusewhilesimultaneouslyincreasingreinforcementforhealthieractivities

•  Appliescontingenciesintheformofreinforcementandconsequencesinordertoreducesubstanceuse

•  Oftenusesavoucher-basedsystemtogivepossiblerewardsforstayingintreatmentorremainingdrug-free

•  A2016systematicreviewfoundthatcontingencymanagementhelpedtodecreaseuseinadiversegroupofsubstanceusedisorders,withatreatmenteffectthatweakenedbutdidnotdisappearfollowingtreatmenttermination1 1Davisetal.PrevMed,2016.

Page 26: Methamphetamine use disorder (+ HIV): Trials, Trends and

ClinicalresponsestoCMinPROPweresimilartoCMdeliveredindrugtreatmentprograms.[…]FurtherexpansionofprogramslikePROPcouldaddresstheincreasingneedsforacceptable,feasible,andcost-

effectivemethamphetaminetreatmentinthisgroupwithexceptionallyhighratesofHIV-infection.

Page 27: Methamphetamine use disorder (+ HIV): Trials, Trends and

Conclusions•  Theprevalenceofmethamphetamineusecontinuestoriseanditisassociatedwithnumerousphysical,psychiatric,andsocialharms

•  MethamphetamineuseisassociatedwithanincreasedriskofcontractingHIVandworseHIVtreatmentoutcomes

•  Evidence-basedtreatmentsareavailableforstimulantusedisorder,psychosocialapproaches(esp.CM)remainthegoldstandardandcanbeimplementedinsettingswithhighratesofHIV

Page 28: Methamphetamine use disorder (+ HIV): Trials, Trends and

Questions?

[email protected]